EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.807
https://www.valueinhealthjournal.com/article/S1098-3015(23)03937-2/fulltext
Title :
EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03937-2&doi=10.1016/j.jval.2023.09.807
First page :
Section Title :
Open access? :
No
Section Order :
10291